100 likes | 103 Views
This proposal aims to address the decline in pancreas transplants and the underutilization of Pancreas After Kidney (PAK) transplants. By providing a guidance document with evidence supporting PAK transplantation, this proposal advocates offering PAK transplants as an alternative to simultaneous pancreas-kidney (SPK) transplants for uremic diabetic candidates with a waiting time of more than 1 year. Analysis of a large cohort of SPK, PTA, and PAK candidates/recipients from 1995-2010 will be conducted to examine kidney and pancreas graft survival, waitlist and recipient mortality, and hazard ratio of patient recipient survival compared to SPK waitlist survival.
E N D
Guidance on the Benefits of Pancreas After Kidney (PAK) Transplantation Pancreas Transplantation Committee
What problem will the proposal solve? • Decline in pancreas transplants, and substantial decline in PAKs Stratta, Robert J., Jonathan A. Fridell, Angelika C. Gruessner, Jon S. Odorico, and Rainer W.g. Gruessner. Pancreas transplantation: A Decade of Decline. Current Opinion in Organ Transplantation 21, no. 4 (August 2016): 386-92. doi:10.1097/mot.0000000000000319.
What problem will the proposal solve? • PAKs are underutilized: • Many uremic diabetic patients who receive a kidney transplant are not offered a subsequent pancreas transplant and miss the potential benefits: • PAK transplant recipients have survival advantage to SPK waiting list candidates • Receiving a pancreas after a kidney increases kidney graft survival • 2003 JAMA paper • Compared PAK patient survival to uremic diabetic patients waiting for a PAK who received a kidney alone, not to SPK waitlist candidate survival (as in current analysis)
What are the proposed solutions? • Provide a guidance document with evidence in support of offering PAK transplants • Guidance document recommends PAK transplantation as an alternative to SPK transplants for diabetic uremic candidates, particularly if the SPK waiting time is > 1 year
Data Analysis • Cohort: 28699 SPK, PTA, PAK candidates/recipients from 1995-2010 • Allows for long term follow up • larger cohort than 2003 JAMA paper • Does not exclude patients with reported creatinine > 2 mg/dl • Contrast with 2003 JAMA paper, which did exclude these patients • Analysis examined: • Kidney and pancreas graft survival across transplant type • Waitlist and recipient mortality by PAK, SPK • Hazard ratio of SPK and PAK patient recipient survival compared to SPK WL survival
How will members implement this proposal? • Transplant hospitals may use this guidance as a resource for staff, for discussions with patients and when considering organ offers • Guidance documents are for voluntary use by members and are not prescriptive of clinical practice
How will the OPTN implement this proposal? • Anticipated Board date: December 3-5, 2017 • Committee will monitor and annually review the number of PAKs performed • UNOS will create an educational component on how to use the guidance
Questions? Jon Odorico, MD Committee Chair jon@surgery.wisc.edu Abigail Fox, MPA Committee Liaison Abigail.fox@unos.org